Asymchem Laboratories (Tianjin) Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Asymchem Laboratories (Tianjin) şirketinin toplam hissedar öz sermayesi CN¥16.6B ve toplam borcu CN¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥18.7B ve CN¥2.1B dir. Asymchem Laboratories (Tianjin) 'in FAVÖK'ü CN¥591.0M faiz karşılama oranı -2 dur. Şirketin CN¥7.2B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

CN¥0

Borç

Faiz karşılama oranı	-2x
Nakit	CN¥7.16b
Eşitlik	CN¥16.63b
Toplam yükümlülükler	CN¥2.06b
Toplam varlıklar	CN¥18.70b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 002821 'nin kısa vadeli varlıkları ( CN¥10.6B ) kısa vadeli yükümlülüklerini ( CN¥1.6B ) aşıyor.

Uzun Vadeli Yükümlülükler: 002821 şirketinin kısa vadeli varlıkları ( CN¥10.6B ) uzun vadeli yükümlülüklerini ( CN¥478.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 002821 borçsuzdur.

Borcun Azaltılması: 002821 şirketinin 5 yıl önce borç/öz sermaye oranı 1.1% iken borcu yok.

Borç Kapsamı: 002821 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 002821 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Asymchem Laboratories (Tianjin) Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Asymchem Creates an Artificial Intelligence Platform to Address Key Challenges in Protein Design

Third quarter 2024 earnings released: EPS: CN¥0.61 (vs CN¥1.45 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Executive VP & Executive Director recently bought CN¥1.8m worth of stock

Asymchem Laboratories (Tianjin) Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 19%

CFO, Senior VP & Executive Director recently bought CN¥4.3m worth of stock

Second quarter 2024 earnings released: EPS: CN¥0.63 (vs CN¥2.94 in 2Q 2023)

Asymchem Laboratories (Tianjin) Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Dividend of CN¥1.80 announced

Asymchem Appoints Cheng Yi Chen as CTO of Small-Molecule Sector

Asymchem Laboratories (Tianjin) Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 28 June 2024

Asymchem Laboratories (Tianjin) Co., Ltd. Approves Final Ordinary Dividend for the Year Ended 31 December 2023, Payable on 12 July 2024

Asymchem Appoints Franck Mevellec as Senior Director, Business Development

New major risk - Revenue and earnings growth

Asymchem Laboratories (Tianjin) Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Asymchem Laboratories (Tianjin) Co., Ltd., Annual General Meeting, Jun 06, 2024

Asymchem Laboratories (Tianjin) Co., Ltd. Proposes Final Ordinary Dividend for the Year Ended 31 December 2023

Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) commences an Equity Buyback Plan for CNY 1,200 million worth of its shares, under the authorization approved on February 29,2024.

Asymchem Laboratories (Tianjin) Co., Ltd. Appoints Hou Xinyi as an Independent Non-Executive Director, Effective 29 February 2024

Asymchem Laboratories (Tianjin) Co., Ltd. Announces Resignation of Wang Qingsong as Independent Non-Executive Director and Committees

Asymchem Laboratories (Tianjin) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

New major risk - Revenue and earnings growth

Now 23% undervalued after recent price drop

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥1.45 (vs CN¥2.71 in 3Q 2022)

Asymchem Laboratories (Tianjin) Co., Ltd. Appoints Sun Xuejiao as Independent Non-Executive Director

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: CN¥2.94 (vs CN¥3.39 in 2Q 2022)

Asymchem Laboratories (Tianjin) Co., Ltd. Implements Final Cash Dividend (A shares) for 2022, Payable on 21 July 2023

Asymchem Laboratories (Tianjin) Co., Ltd. Declares Final Dividend for the Year Ended 31 December 2022. Payable on 21 July 2023

Full year 2022 earnings released: EPS: CN¥9.02 (vs CN¥3.15 in FY 2021)

Asymchem Laboratories (Tianjin) Co., Ltd. to Report Fiscal Year 2022 Results on Mar 31, 2023

Asymchem Laboratories (Tianjin) Co., Ltd. Announces Resignation of Zhang Kun as an Independent Non-Executive Director

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥2.71 (vs CN¥0.79 in 3Q 2021)

Investor sentiment deteriorated over the past week

Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) commences an Equity Buyback Plan for CNY 800 million worth of its shares, under the authorization approved on September 2, 2022.

Second quarter 2022 earnings released: EPS: CN¥3.38 (vs CN¥0.81 in 2Q 2021)

Asymchem Laboratories (Tianjin) Co., Ltd. to Report First Half, 2022 Results on Aug 25, 2022

Asymchem Laboratories (Tianjin) Co., Ltd. Provides Earnings Guidance for the Period Ended June 30, 2022

Now 27% undervalued after recent price drop

Asymchem Laboratories (Tianjin) Co., Ltd. Approves Cash Dividend for the Year 2021

Now 21% undervalued after recent price drop

Asymchem Laboratories (Tianjin) Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 21 July 2022

Less than half of directors are independent

Asymchem Laboratories (Tianjin) Co., Ltd., Annual General Meeting, Jun 09, 2022

Asymchem Laboratories (Tianjin) Co., Ltd. to Report Q1, 2022 Results on Apr 20, 2022

Asymchem Laboratories (Tianjin) Co., Ltd. Proposes Final Cash Dividend for the Year Ended December 31, 2021

Asymchem Laboratories (Tianjin) Co., Ltd. Announces Final Dividend for the Year Ended December 31, 2021

Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) entered into an agreement to acquire remaining 81.82% stake in Snapdragon Chemistry, Inc. for $57.9 million.

Investor sentiment deteriorated over the past week

Asymchem Laboratories (Tianjin) Co., Ltd. Provides Group Earnings Guidance for the Year Ending December 31, 2021

Less than half of directors are independent

Asymchem Laboratories (Tianjin) Co., Ltd. has filed an IPO in the amount of HKD 7.550314 billion.

Asymchem Laboratories (Tianjin) Co., Ltd. Announces Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.64 (vs CN¥0.47 in 1Q 2020)

Asymchem Laboratories (Tianjin) Co., Ltd. to Report Fiscal Year 2020 Results on Apr 16, 2021

New 90-day low: CN¥256

Asymchem Laboratories (Tianjin) Co., Ltd. Elects Zhang Ting as Non-Independent Director

New 90-day high: CN¥316

New 90-day high: CN¥297

New 90-day high: CN¥288

Asymchem Laboratories (Tianjin) Co., Ltd. to Report Q3, 2020 Results on Oct 24, 2020

New 90-day high: CN¥274

Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) signed an equity transfer agreement to acquire Tianjin Guanqin Pharmaceutical Technology Co., Ltd. from Tianjin Shengqin Pharmaceutical Technology Partnership (Limited Partnership) and Liang Qing for CNY 30 million.

New 90-day high - CN¥250

Asymchem Laboratories (Tianjin) Co., Ltd. to Report First Half, 2020 Results on Aug 08, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin